Many chronic myeloid leukemia (CML) patients acquire resistance to the BCR-ABL inhibitor imatinib by specific BCR-ABL mutations, particularly the T315I gate-keeper mutation. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.